The life sciences industry is changing. Fast.
Over the past 20 years, disruptive technologies, business models, and platforms have reshaped entire industries. Just think: do we transit, vacation, or bank the way we did just five years ago? Those very same shifts are now making their way to through the biotech and pharmaceutical industry.
We started Biotech2050 to chronicle and study these disruptions. Biotech2050 is a podcast exploring the disruptive forces influencing the next half-century of the life sciences industry. Our charter is two fold: i) identify transformational changes poised to reshape the industry, and ii) engage intellectually with the pioneers advancing these changes.
We engage with these trailblazers by creating a platform to share their insights on key topics across the industry. The ensuing discussions and interactions aim to inform a broader community of the evolution of biopharma and foster new collaborations across participating entities. Our podcast is meant to inspire budding entrepreneurs, rising leaders, and industry veterans across biotech and pharma industry.
We welcome all members of the biopharma community to listen in on our conversations and participate as well.
Alok Tayi, PhD
Host
Alok Tayi, PhD is the Co-founder and CEO of Vibe Bio. Vibe is a therapeutics company that partners with patient communities to develop new medicines. Previously, Alok spent 10 years as an entrepreneur and life sciences software executive. He started and built the Life Sciences business unit at Egnyte, was a YCombinator-backed founder and started two SaaaS companies. Prior to his career in software, Alok spent over 15 years as a scientist, including postdoctoral work at Harvard University with George Whitesides. Alok holds a PhD from Northwestern University and BS from Cornell University.
Rahul Chatuverdi
Host
Rahul Chaturvedi is the Founder and CEO of Clora, the leading marketplace where people go to discover, build, and manage on-demand life science teams. Prior to founding Clora in 2017, Rahul was the head of clinical development at several biopharma companies, such as Kaleido Biosciences (NSDQ: KLDO) and Avedro (acquired by Glaukos). Rahul has successfully led the development activities for 20+ Phase II/III programs that have resulted in 6 product approvals to date. Rahul holds a bachelor of science degree from Brandeis University.
Thank you to all our guests and listeners
